Samer Al Hadidi, Associate Professor at UAMS – University of Arkansas for Medical Sciences, shared a thread post on X:
“Oral myeloma- functional high risk from the consortium.
Thought provoking , the whole definition of functional high risk is evolving. Baseline treatment as well as current more effective therapies.
This may help in identifying need for BCMA CAR-T vs. ongoing therapy with BCMA BsAb.”
More updates from ASH25 on OncoDaily.
